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EphB4 and ephrinB2 expressions in ovarian cancers were studied to analyse EphB4/ephrinB2 functions against clinical backgrounds.
EphB4 and ephrinB2 were dominantly localised in ovarian cancer cells of all cases studied. Both the histoscores and mRNA levels of
EphB4 and ephrinB2 significantly increased with clinical stages (IoIIoIIIoIV, Po0.001) in ovarian cancers, although there was no
significant difference in EphB4 and ephrinB2 histoscores or in mRNA levels according to histopathological types. EphB4 as well as
ephrinB2 histoscores in cancer cells correlated with the corresponding mRNA levels in each case (EphB4, Po0.001; ephrinB2,
Po0.001). The 24-month survival rates of the 36 patients with high EphB4 and ephrinB2 expression were poor (25 and 27%,
respectively), while for the other 36 patients with low EphB4 and ephrinB2 expression, they were significantly higher (68 and 64%,
respectively). Therefore, EphB4/ephrinB2 may function in tumour advancement and coexpression of the Eph/ephrin system may
potentiate tumour progression leading to poor survival. Thus, EphB4/ephrinB2 can be recognised as a novel prognostic indicator in
the primary tumours of ovarian cancers.
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Receptor tyrosine kinases (RTKs) are a diverse group of
transmembrane proteins that, upon receiving an external stimulus,
respond by transmitting a signal to the inside of the cell and thus
control the cell shape, proliferation, differentiation and migration
(Hunter et al, 1992; Dodelet and Pasquale, 2000; Lamorte and Park,
2001). In that sense, tyrosine kinase receptors have significant
roles in normal physiology and in oncogenesis (Nakamoto and
Bergemann, 2002). Of all the RTKs that are found in the human
genome, the Eph receptors constitute the largest subfamily of RTK
proteins and all members share a similar structure including a
ligand binding extracellular domain, a single transmembrane
domain and an intracellular tyrosine kinase domain. As a unique
class of RTKs, the Eph family, first discovered in a human cDNA
library screen for homologous sequences to the viral oncogene vfps
(Hirai et al, 1987), consists of at least 14 receptors and 8 ligands
(Gale et al, 1996; Eph Nomenclature Committee, 1997). Unlike
other families of RTKs, which bind soluble ligands, Eph receptors
interact with cell-surface-bound ephrin ligands. Based on binding
preference and sequence homology, the Eph receptors have been
divided into two subclasses, EphA (A1–A8) and EphB (B1–B6)
(Gale et al, 1996). EphA receptors are anchored on plasma
membranes through a glycosylphosphatidylinositol linkage and
bound by their ligand ephrinA (A1–A5), whereas EphB receptors
are bound by ephrinB (B1–B3) and tethered to the membrane by a
transmembrane domain (Gale et al, 1996). EphA4 is an exception
in that it can bind A type and most B type ligands.
EphB4 selectively binds ephrinB2 and no other ephrinB ligands
(Brambilla et al, 1995; Sakano et al, 1996). EphrinB is constituted
of transmembrane proteins with an intracellular domain that can
elaborate reverse signalling (Davis et al, 1994; Gale and
Yancopoulos, 1997). Ligand–receptor binding leads to protein
clustering followed by receptor activation (Davis et al, 1994).
Besides, both Ephs and ephrins are membrane bound and
therefore binding and activation require cell-to-cell interaction
rather than long-range communication; they mediate bidirectional
signalling cascades (Fuller et al, 2003). When EphB4 is activated by
ephrinB2, multiple tyrosine sites are phosphorylated and the
kinase domains activated, although soluble forms of either
ephrinA or ephrinB cannot activate their receptors (Davis et al,
1994; Katoh and Pasquale, 1999).
EphB4 plays an important role in a variety of processes during
embryonic development, including pattern formation, cell aggre-
gation and migration, segmentation, neural development, angio-
genesis and vascular hierarchical remodelling (Pasquale, 1997;
Gerety et al, 1999; Tickle and Altabef, 1999). EphrinB2 participates
in vascular remodeling, maturation and directed growth (Tickle
and Altabef, 1999). Coexpression of both EphB4 and ephrinB2 at
high levels in malignancies including melanoma, neuroblastoma
and cancers of the prostate, breast, lungs, oesophagus, gastrium,
colorectum and uterine endometrium dysregulates cell adhesion
and cell motility in tumours (Kyokawa et al, 1994; Vogt et al, 1998;
Easty et al, 1999; Walker-Daniels et al, 1999; Tang et al, 2000;
Miyazaki et al, 2003). To discover additional molecular therapeutic
targets that may be incorporated into a multimodality regimen for
the treatment of ovarian cancer, we studied the expression and
localisation of the EphB4 receptor and the corresponding ephrinB2
ligand in ovarian cancers to analyse EphB4/ephrinB2 functions
against clinical backgrounds.
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sMATERIALS AND METHODS
Patients and tissues
Prior informed consent for the following studies was obtained
from all patients and the study was approved by the Research
Committee for Human Subjects, Gifu University School of
Medicine. Seventy-two patients ranging from 45 to 79 years of
age with ovarian cancers (15 stage I cases, 19 stage II cases, 28
stage III cases and 10 stage IV cases and 13 cases of clear cell
adenocarcinoma, 8 cases of endometrioid adenocarcinoma, 18
cases of mucinous cystadenocarcinoma, 15 cases of serous
cystadenocarcinoma and 18 cases of serous papillary cystadeno-
carcinoma) underwent surgical resection, which produced macro-
scopically disease-free status, at the Department of Obstetrics and
Gynecology, Gifu University School of Medicine, between September
1997 and March 2003. None of the patients had received any
preoperative therapy. The tissues of ovarian cancer were obtained
immediately after surgery. The tissues for RNA isolation were
snap-frozen and stored at  801C, and those for immunohisto-
chemistry were fixed with 10% formalin and embedded in paraffin
wax. The clinical backgrounds of ovarian cancer were evaluated by
the International Federation of Gynecology and Obstetrics (FIGO)
classification (FIGO News, 1989).
Immunohistochemistry
Four-micrometre-thick sections of formalin-fixed paraffin-em-
bedded tissue samples from ovarian cancers were cut with a
microtome and dried overnight at 371C on a silanised slide (Dako,
Carpinteria, CA, USA). The protocol of universal Dako Labelled
Streptavidin-Biotin kit (Dako) was followed for each sample.
Samples were deparaffinised in xylene at room temperature for
30min, rehydrated with graded ethanol and washed in phosphate-
buffered saline (PBS). The samples were then placed in 10mM
citrate buffer (pH 6.0) and boiled in a microwave for 10min for
epitope retrieval. Endogenous peroxidase activity was quenched by
incubating tissue sections in 3% H2O2 for 10min. The primary
antibodies, rabbit EphB4 (sc-5536, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and rabbit ephrinB2 (sc-1010, Santa Cruz)
were used overnight at 41C at dilutions of 1:100 and 1:75,
respectively. The slides were washed and biotinylated anti-rabbit
secondary antibody (Dako) was applied for 30min. After rinsing in
PBS, streptavidin-conjugated horseradish peroxidase (Dako) was
added for 30min. Slides were then washed and treated with the
chromogen 3,30-diaminobenzidine (Dako) for 5min, rinsed in
PBS and counterstained with Mayers haematoxylin, dehydrated
in graded ethanol, cleared in xylene and coverslipped with a
mounting medium, Entellan New (Merck, Darmstadt, Germany).
Rabbit preimmune animal serum (Dako) was used for
negative controls instead of the primary antibody for EphB4 or
ephrinB2.
Assessment of histochemical score
All sections of immunohistochemical staining for EphB4 and
ephrinB2 were evaluated in a semiquantitative fashion by two
pathologists according to the method described by McCarty et al
(1985), which considers both the intensity and the percentage of
cells stained at each intensity. Intensities were classified as 0 (no
staining), 1 (weak staining), 2 (distinct staining), 3 (strong
staining) and 4 (very strong staining). For each stained section, a
value-designated histochemical score (histoscore) was obtained
using the algorithm, histoscore¼
P
(iþ1)Pi, where i and Pi
represent the intensity and percentage of cells that stain at each
intensity, respectively, and the corresponding histoscores were
calculated separately.
Preparation of standard template for real-time reverse
transcription–PCR
Internal standard template for real-time PCR was produced by
PCR amplification using the primers for EphB4 gene, 2201–2682
in the cDNA (EphB4-TS: 50-AGATCGATGTCTCCTACGTC-30
and EphB4-TAS: 50-GATTCCTGGAGGAGAACTCT-30) and for
ephrinB2 gene, 570–989 in the cDNA (ephrinB2-TS: 50-GTCCAGA
ACTAGAAGCTGGT-30 and ephrinB2-TAS: 50-GTACATCGTCCAG
GAGATGC-30). The DNA template was purified using a GeneClean
II kit (Qbiogene, Irvine, CA, USA). The copy numbers of the
standard template were determined to quantify EphB4 and
ephrinB2 mRNA levels in samples for real-time reverse transcrip-
tion–PCR (RT–PCR).
Real-time RT–PCR
Total RNA was extracted with the acid guanidinium thiocyanate–
phenol–chloroform method (Chomczynski and Sacchi, 1987). The
total RNA (3mg) was reverse transcribed using Moloney murine
leukaemia virus reverse transcriptase (MMLV-RT, 200Uml
 1;
Invitrogen, Carlsbad, CA, USA) and the following reagents:
250mM Tris-HCl, pH 8.3, 375mM KCl, 15mM MgCl2, 0.1 M
dithiothreitol, 10mM deoxynucleotide (deoxyadenosine, deoxythy-
midine, deoxyguanosine and deoxycytidine) triphosphates
(dNTPs) mixture and random hexamers (Invitrogen) at 371C for
1h. The reaction mixture was heated for 5min at 941C to inactivate
MMLV-RT.
Real-time PCR reaction was performed with a Takara Ex Taq
R-PCR kit, version 1.0 (Takara, Otsu, Japan), using a smart cycler
system (Cepheid, Sunnyvale, CA, USA). The reaction solution
(25ml) contained Takara Ex Taq HS (5Uml
 1), 10 R-PCR buffer,
250mM Mg
2þ solution, 10mM dNTP mixture, SYBR Green I
(1:1000 dilution; Cambrex Bio Science Rockland Inc., Rockland,
ME, USA) and 20mM of the primers for EphB4 gene, 2501–2625
in the cDNA (EphB4-S: 50-ACGGACAGTTCACAGTCATC-30
and EphB4-AS: 50-GCAACATCCTAGTCAACAGC-30) and
for ephrinB2 gene, 679–785 in the cDNA (ephrinB2-S:
50-CAACATCCTCGGTTCCGAAG-30 and ephrinB2-AS: 50-CCTC-
TTGCTGAAGTACCGGA-30) with the transcribed total RNA from
the tissue and a serially diluted standard template. The real-time
PCR reactions were initially denatured by heating at 951C for 30s,
followed by 40 cycles consisting of denaturation at 941C for
10s, annealing at 551C for 5s and extension at 721C for 20s. A
strong linear relationship between the threshold cycle and the log
concentration of the starting DNA copy number was always shown
(correlation coefficient 40.99). Quantitative analysis was
performed to determine the copy numbers of each sample.
Statistical analysis
EphB4 and ephrinB2 mRNA levels were determined from three
parts taken from each tumour, and each sample was analysed in
triplicate. The differences in the histoscores and mRNA levels of
EphB4 and ephrinB2 were analysed by Student’s t-test. The
correlation coefficients were evaluated both by linear regression
analysis and bivariate Pearson correlation. Survival rates were
calculated using the Kaplan–Meier method and analysed by the
log-rank test. Differences were considered significant when P was
less than 0.05.
RESULTS
All the ovarian cancer specimens revealed strong staining for
EphB4 and ephrinB2 in the cancer cells and very faint staining in
vascular endothelial cells. Positive staining in the cell membrane of
the cancer cells has been shown for both EphB4 and ephrinB2.
Immunohistochemical staining for EphB4 and ephrinB2 of a
representative case of clear cell carcinoma of the right ovary is
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sshown in Figure 1. Both EphB4 and ephrinB2 mRNA seemed to be
expressed mainly from the cancer cells. EphB4 as well as ephrinB2
histoscores in cancer cells correlated with the corresponding
mRNA levels in each case (EphB4, y¼9.245xþ133.49, r¼0.522,
Po0.001; ephrinB2, y¼1.107xþ147.57, r¼0.561, Po0.001), as
shown in Figure 2.
Both EphB4 and ephrinB2 histoscores in cancer cells and mRNA
levels in ovarian cancers significantly increased according to
clinical stage (IoIIoIIIoIV, Po0.001), as shown in Figure 3.
There was no significant difference in histoscores or mRNA levels
of EphB4 and ephrinB2 according to histopathological type, as
shown in Figure 4.
We analysed the prognosis of the 72 patients who underwent
surgical resection. EphB4 histoscore of 170 and 4.0 10
5 DNA
copy per mg total RNA in EphB4 mRNA level and ephrinB2
histoscore of 192 and 3.9 10
6 DNA copy per mg total RNA in
ephrinB2 mRNA level were the median values, and were adopted to
divide the 72 patients into two groups of 36 patients each.
The 24-month survival rate of the 36 patients with high EphB4
(cases with EphB4 histoscore over 170; the same as those with
EphB4 EphrinB2
EphB4 negative control EphrinB2 negative control
Figure 1 Immunohistochemical staining for EphB4 and ephrinB2 in ovarian cancers (original magnification  200). A representative case of clear cell
carcinoma of the right ovary is shown. Rabbit EphB4 and ephrinB2 antibodies (Santa Cruz) were used at dilutions of 1:100 and 1:75, respectively, as
primary antibodies. Dark brown staining represents positive for EphB4 and ephrinB2 antigen. Bars¼100mm.
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Figure 2 Correlation of EphB4 and ephrinB2 histoscores with mRNA levels in ovarian cancers. Correlation between EphB4 histoscores in cancer cells
with mRNA levels and ephrinB2 histoscores in cancer cells with mRNA levels in ovarian cancers is shown. Both EphB4 and ephrinB2 histoscores and mRNA
levels were determined by immunohistochemistry and real-time RT–PCR, respectively. Each level is the mean±s.d. of nine determinations.
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5 DNA copy per mg total RNA)
was 25%, and the rate of the other 36 patients with low EphB4
(cases with EphB4 histoscore below 170; EphB4 mRNA levels
below 4.0 10
5 DNA copy per mg total RNA) was 68%. The
survival rate of the 36 patients with high ephrinB2 (cases with
ephrinB2 histoscore over 192; the same as those with ephrinB2
mRNA levels over 3.9 10
6 DNA copy per mg total RNA) was 27%,
while that of the other 36 patients with low ephrinB2 (cases with
ephrinB2 histoscore below 192; ephrinB2 mRNA levels below
3.9 10
6 DNA copy per mg total RNA) was 64%. There was a
significant difference (Po0.05 in EphB4 and Po0.01 in ephrinB2)
between the 24-month survival rates of the 36 patients with high or
low histoscores and mRNA levels of EphB4 and ephrinB2, as
shown in Figure 5.
DISCUSSION
High levels of Eph expression have been reported in various
cancer cell lines and cancer specimens, including cancer of
the breast (Zantek et al, 1999; Zelinski et al, 2001), prostate
(Walker-Daniels et al, 1999), colon (Rosenberg et al, 1997),
oesophagus (Miyazaki et al, 2003), lung (Kinch et al, 2003),
uterine endometrium (Alam et al, 2007) and in metastatic
melanoma (Easty and Benett, 2000). Besides, high levels of Eph
expression are found to be associated with more aggressive
behaviour in tumours and tumour models, showing tumorigenic
and metastatic functions (Rosenberg et al, 1997). Increased
expression of ephrinB in high-grade ovarian tumours and clear
cell and serous carcinomas correlated with tumour aggressiveness,
which was associated with higher rates of disease recurrence and
poor survival rate (Castellvi et al, 2006). Correlated expressions of
EphB4 and ephrinB3 with strong expression in epithelial ovarian
cancer histotypes address the possibility of involvement of
paracrine/juxtacrine signalling through tumour progression
(Castellano et al, 2006). Elevated expression and activity of Eph
receptors have been correlated with the growth of solid tumours
(Easty et al, 1999). In addition, a high expression of ephrins
may be associated with an increased potential for tumour
growth, tumorigenicity and metastasis (Kyokawa et al, 1994; Vogt
et al, 1998; Easty et al, 1999; Walker-Daniels et al, 1999; Tang et al,
2000; Miyazaki et al, 2003). Among them, EphB4 and ephrinB2
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Figure 3 EphB4 and ephrinB2 histoscores and mRNA levels in ovarian cancers classified according to clinical stages. The histoscores and mRNA levels of
EphB4 and ephrinB2 were determined by immunohistochemistry and real-time RT–PCR, respectively. Clinical stages of ovarian cancer were assessed
according to the FIGO classification. Each level is the mean±s.d. of nine determinations. Alive and dead cases are numbered in open circles and closed
circles, respectively; *Po0.05; **Po0.001.
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sarbitrate the enhanced proliferation, migration and metastatic
potential of tumour cells (Vogt et al, 1998; Easty et al, 1999;
Brantley et al, 2002; Cheng et al, 2002; Lawrenson et al, 2002;
Pawson, 2002).
EphA2 receptor and its ephrinA1 and ephrinA5 ligands have
shown increased expression in ovarian tumours with poor survival
rates (Herath et al, 2006). In the present study, a significant
difference in patient prognoses was found between high and low
expression levels of both EphB4 and ephrinB2, which increased
during advancement from stage I to stages II, III and IV.
Overexpression of EphB4 and ephrinB2 in tumour cells suggests
that EphB/ephrinB signalling drives destabilisation, which can also
affect cell–matrix attachment, and thereby promote invasion and
metastasis (Kyokawa et al, 1994).
Accumulating evidence suggests that overexpression or co-
expression of Eph family RTKs and their ligands could promote
tumour progression. Overexpression of EphB4 and ephrinB2 has
been observed in malignant colonic epithelium and uterine
endometrial cancer (Sinha et al, 2003; Alam et al, 2007). EphA2
was found to be expressed at high levels in metastatic melanoma
cells in comparison with normal melanocytes (Easty et al, 1995).
Also, ephrinB2 was highly expressed in primary and metastatic
melanomas compared to benign melanocytic nevi (Vogt et al,
1998). Furthermore, the expression of ephrinA1 and the upregulation
of its receptor, EphA2, were found during the course of melanoma
progression (Vogt et al, 1998). EphA1 has also been shown to be
oncogenic in the classical 3T3 fibroblast assay and coexpression of
an ephrin ligand could generate an autocrine loop (Maru et al,
1990).
Noren et al (2004) proposed a proangiogenic role for EphB4
in tumour progression where the plausible linkage between the
EphB4 ectodomain on tumour cells and ephrinB2 in the
vasculature seems to facilitate the formation of blood vessels and
remodelling (Noren et al, 2004). Consistent with this, in our
present study, weak staining in vascular endothelial cells, although
not very significant, may lead to the hypothesis that there is
localised EphB4 activation in the cell membrane of cancer cells that
are in contact with blood vessels, which might promote metastasis
and further tumour progression. Besides, EphB4 receptor and
ephrinB2 ligand were significantly higher and overexpressed with
tumour advancement in ovarian cancer regardless of histopatho-
logical types. Thus, data from our present study suggest that
autocrine stimulation by EphB4 and ephrinB2 coexpression might
mediate the advancement of ovarian cancer. The coexpression of
EphB4/ephrinB2 may potentiate tumour advancement leading to
poor survival and can be recognised as a novel prognostic
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block the EphB4/ephrinB2 signalling pathway using soluble
ephrinB2, an attractive therapeutic strategy might be developed
in the future.
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